Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

计划入组 571 人 · 首次发布于 2020 年 6 月 1 日

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

计划入组 49 人 · 首次发布于 2016 年 6 月 16 日

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

计划入组 30 人 · 首次发布于 2026 年 7 月 13 日

HOXB7 inhibitors (drug-resistant breast cancer)

TI-I-100

drug candidate

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Redpharm Drug

United States

Chain Drug Consortium

United States

ACROBiosystems and DAAN Biotherapeutics Form Strategic Alliance to Accelerate Precision Immuno-Oncology Development

Black Diamond Therapeutics Reports Promising Phase 2 Data for Silevertinib in EGFR-Mutant Cancers

Strategies Emerge to Combat Acquired Resistance in EGFR-Mutant NSCLC